Shiba Inu (SHIB) billionaire addresses are stealthily increasing holdings, according to data from on-chain analytics company IntoTheBlock, as a major boost for the Shiba Inu ecosystem approaches.
Shiba Inu billionaire addresses, notably those that possess 100 billion to 1 trillion SHIB, were found to have increased their holdings the most over the past 30 days, which indicates that this group of holders has been steadily accumulating.
Shiba Inu holders who own more than 100 billion to one trillion SHIB have experienced accumulation from all levels of holders over the past 30 days, but they have also seen a tremendous 10.36% growth in their holdings.
The increase in balances is nonetheless substantial given that this class of holders owns SHIB worth trillions of dollars in total.
The amount owned by Shiba Inu huge billionaire addresses increased from 103.5 trillion Shiba Inu to 105.99 trillion SHIB only last week, from July 3 to July 10. The variation amounts to a rise of 2.4 trillion SHIB.
Shiba Inu continues to show commendable advancements in every area as the development team and SHIB authorities strive to spread awareness of SHIB and its associated initiatives on a global scale.
Shiba Inu leader Shytoshi Kusama recently announced the revamping of the official SHIB token website in a tweet. This also holds true for various Shiba Inu ecology project webpages.
Kusama tweeted, “We are happy to unveil new branding for Shib.io and other Shibarmy websites as the Summer of Shibarium continues.
The announcement was welcomed enthusiastically by the neighbourhood, giving the impression that the SHIB ecosystem may be getting something fresh and significant.
The debut of the Shibarium mainnet, which is anticipated to fundamentally strengthen the Shiba Inu ecosystem tokens (SHIB, BONE, and LEASH), is widely anticipated by the Shiba Inu community.
According to rumours, the event will take place in August in Toronto, just around the time of the Blockchain Futurist conference. More than 7,000 applications for Shibarium beta intake forms have been received by the team, indicating that interest in the drug is still growing.
